ARS Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ARS Pharmaceuticals, Inc. (SPRY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $300.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $200.00K, a 95.65% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $100.00K, a 92.31% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $1.10M, a 88.04% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $2.10M, a 0.00% change year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $9.10M, a 38.10% decline from fiscal 2024.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $14.70M, a 72.94% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $8.50M, a 608.33% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $1.20M, a 1100.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $300.00K 10-Q · filed 2026-08-13 | $1.40M derived: sum of 3 quarters · filed 2026-08-13 | $3.50M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-15 | $1.20M derived: sum of 2 quarters · filed 2026-05-15 | $3.30M derived: sum of 3 quarters · filed 2026-05-15 | $7.90M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $3.20M derived: sum of 2 quarters · filed 2026-03-09 | $7.80M derived: sum of 3 quarters · filed 2026-08-13 | $9.10M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $6.70M derived: sum of 2 quarters · filed 2026-08-13 | $8.00M 10-Q · filed 2025-11-10 | $17.20M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $4.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $5.90M 10-Q · filed 2026-08-13 | $15.10M derived: sum of 3 quarters · filed 2026-08-13 | $17.20M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $1.30M 10-Q · filed 2026-05-15 | $10.50M derived: sum of 2 quarters · filed 2026-05-15 | $12.60M derived: sum of 3 quarters · filed 2026-05-15 | $15.00M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | $9.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $11.30M derived: sum of 2 quarters · filed 2026-03-09 | $13.70M derived: sum of 3 quarters · filed 2026-03-09 | $14.70M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.50M derived: sum of 2 quarters · filed 2025-11-10 | $5.50M 10-Q · filed 2025-11-10 | $6.10M derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2024-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $3.40M 10-Q · filed 2025-08-13 | $4.00M derived: sum of 3 quarters · filed 2025-08-13 | $6.20M derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $1.00M 10-Q · filed 2025-05-14 | $1.60M derived: sum of 2 quarters · filed 2025-05-14 | $3.80M derived: sum of 3 quarters · filed 2025-05-14 | $7.10M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $2.80M derived: sum of 2 quarters · filed 2025-03-20 | $6.10M derived: sum of 3 quarters · filed 2025-03-20 | $8.50M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $5.50M derived: sum of 2 quarters · filed 2024-11-13 | $7.90M 10-Q · filed 2024-11-13 | $7.90M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $5.70M 10-Q · filed 2024-08-06 | $5.70M derived: sum of 3 quarters · filed 2024-08-06 | $5.70M derived: sum of 4 quarters · filed 2024-08-06 | |||
| 2023-03-31 | $2.40M 10-Q · filed 2024-05-09 | $2.40M derived: sum of 2 quarters · filed 2024-05-09 | $2.40M derived: sum of 3 quarters · filed 2024-05-09 | $3.57M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $1.17M derived: sum of 3 quarters · filed 2024-03-21 | $1.20M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.17M derived: sum of 2 quarters · filed 2023-11-09 | $1.20M 10-Q · filed 2023-11-09 | $1.79M 10-Q · filed 2022-11-02 | -$421.00K derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.20M 10-Q · filed 2023-08-10 | $43.00K 10-Q · filed 2022-08-11 | -$421.00K derived: sum of 3 quarters · filed 2023-08-10 | -$3.33M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $34.00K 10-Q · filed 2022-05-12 | -$1.59M derived: sum of 2 quarters · filed 2023-03-23 | -$4.50M derived: sum of 3 quarters · filed 2023-03-23 | -$4.09M derived: sum of 4 quarters · filed 2023-03-23 | |||
| 2021-12-31 | -$1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$4.53M derived: sum of 2 quarters · filed 2023-03-23 | -$4.13M derived: sum of 3 quarters · filed 2023-03-23 | $100.00K 10-K · filed 2023-03-23 | $7.70M 10-K · filed 2022-03-31 | ||
| 2021-09-30 | -$2.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$2.51M derived: sum of 2 quarters · filed 2021-11-10 | $1.72M 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $407.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $4.63M 10-Q · filed 2021-08-12 | |||||
| 2021-03-31 | $4.23M 10-Q · filed 2021-05-13 | ||||||
| 2020-12-31 | $100.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |